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Background: Health care policy-makers look for prescribing indicators at the population level to evaluate the
performance of prescribers, improve quality and control drug costs. The aim of this research was to; (i) estimate
the level of variation in potentially inappropriate prescribing (PIP) across prescribers in the national Irish older
population using the STOPP criteria; (ii) estimate how reliably the criteria could distinguish between prescribers
in terms of their proportion of PIP and; (iii) examine how PIP varies between prescribers and by patient and
prescriber characteristics in a multilevel regression model.
Methods: 1,938 general practitioners (GPs) with 338,375 registered patients’ ≥70 years were extracted from the
Health Service Executive Primary Care Reimbursement Service (HSE-PCRS) pharmacy claims database. HSE-PCRS
prescriptions are WHO ATC coded. Demographic data for claimants’ and prescribers’ are available. Thirty STOPP
indicators were applied to prescription claims in 2007. Multilevel logistic regression examined how PIP varied
between prescribers and by individual patient and prescriber level variables.
Results: The unadjusted variation in PIP between prescribers was considerable (median 35%, IQR 30-40%). The
STOPP criteria were reliable measures of PIP (average >0.8 reliability). The multilevel regression models found that
only the patient level variable, number of different repeat drug classes was strongly associated with PIP (>2 drugs v
none; adjusted OR, 4.0; 95% CI 3.7, 4.3). After adjustment for patient level variables the proportion of PIP varied fourfold
(0.5 to 2 times the expected proportion) between prescribers but the majority of this variation was not significant.
Conclusion: PIP is of concern for all prescribers. Interventions aimed at enhancing appropriateness of prescribing
should target patients taking multiple medications.
Keywords: Potentially inappropriate prescribing, General practice, Prescriber variation, STOPP, Older populationsBackground
Clinical practice guidelines and prescribing indicators
have become a common feature in many healthcare sys-
tems in an attempt to reduce unwarranted physician
variation in medical care, improve quality and control
drug costs [1]. In particular, improving the quality of
drug prescribing in older populations is a priority due to
the association between potentially inappropriate pre-
scribing (PIP) and increases in patient morbidity, mortal-
ity, adverse drug events (ADEs), hospitalisation and
healthcare costs [2,3]. A number of indicators of PIP
have been developed to evaluate prescribing consisting* Correspondence: cacahir@tcd.ie
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unless otherwise stated.of drugs to be avoided in older people independent of
diagnosis and in the context of certain diagnoses [4-6].
There has been little research on the prevalence of PIP
in primary care populations or how it varies between
both patients and general practitioners (GPs) [7]. The
focus to date has mainly been on variation in prescribing
volumes and costs which can have low validity with pre-
scribers [8]. Quantifying and understanding the variation
in PIP is important for planning interventions and the
development of guidelines and incentives to improve
prescribing quality in older populations [1]. It can also
provide information for performance management pur-
poses by identifying prescribers with particularly high
rates of PIP for further investigation [9].
The aim of this study was to examine the variation be-
tween GPs in the prevalence of PIP in the national Irishtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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teria. The main objectives were to: (i) estimate the level
of variation in PIP across the distribution of GPs; (ii) es-
timate how reliably the STOPP criteria could distinguish
between GPs in terms of the proportion of PIP pre-
scribed; and (iii) examine how PIP varies between GPs
and by patient and GP characteristics associated with
PIP in a multilevel regression model.
Methods
Study population
This was a national population study of patients aged ≥
70 years in Ireland in 2007 dispensed medication through
the Primary Care Reimbursement Service of the Health
Service Executive in Ireland (HSE-PCRS) pharmacy claims
database. The HSE-PCRS provides free health services in-
cluding medications to eligible persons in Ireland. It is
means tested for those < 70 years, and free to all those
≥70 years between July 2001 and December 2008. It is
estimated that over 97% of older patients nationally avail
of the scheme [10]. Prescriptions are coded using the
WHO ATC classification system [11]. Prescriber and pa-
tient socio-demographic information, defined daily doses
(DDD), strength, quantity, method and unit of drug ad-
ministration, an urban/rural classification and a measure
of practice deprivation is available [12]. Patients receiving
prescriptions from more than one practitioner were
assigned to the practitioner who prescribed for >3 con-
secutive months. Where more than one practitioner pre-
scribed over a period of >3 months, the patient was
assigned to their most recent practitioner.
Measuring PIP
Thirty STOPP criteria were applied to prescription
claims data for the study population. Details of the appli-
cation of the STOPP criteria to the HSE-PCRS pharmacy
claims database have been described previously [13].
The thirty criteria were considered applicable to phar-
macy claims data without diagnosis information on a
consensus basis by an expert panel of five members
in geriatric pharmacotherapy, clinical pharmacology,
pharmacoepidemiology and academic general practice
(Additional file 1). Prescription drugs for the treatment
of certain disease conditions were identified and used as
proxies for diagnosis where possible e.g. dementia (ATC,
N06D), Parkinson’s disease (ATC, N04) [13] The thirty
STOPP criteria were also included in a composite binary
indicator defined as whether or not a patient had re-
ceived any PIP indicator. The number of different repeat
drug classes was measured for each patient [13,14].
Estimating reliability
The reliability of the STOPP indicators in distinguishing
between GPs was determined based on previous researchand a description of this methodology is provided [7]. The
reliability coefficient measures how confident one can be
that the observed differences in PIP between GPs result
from real differences in the quality of GP prescribing. Reli-
ability increases as variation between GPs increases and
with the number of patients per GP [7]. STOPP indicators
may be reliable for GPs with a large number of patients
but not for GPs with small number of patients and in
order to compare GPs STOPP indicators must have ad-
equate reliability for the majority of GPs. Reliability varies
between 0 (completely unreliable) and 1 (completely reli-
able) with > 0.7 (70%) indicating acceptable reliability and
reliabilities of 0.8-0.9 (80-90%) are preferable for clinical
governance, such as paying GPs for their performance on
certain quality indicators [9].
Data analysis
The overall prevalence of PIP and the prevalence per in-
dividual STOPP criteria were calculated. The proportion
of PIP prescribing (STOPP composite indicator) for each
GP is also presented. Reliability was measured by esti-
mating the intracluster correlation coefficient (ICC) for
each STOPP indicator and the composite indicator in a
two level random intercept logistic model with no ex-
planatory variables (“empty model”). Reliability was cal-
culated using the Spearman-Brown prophecy formula
based on median number of patients aged ≥ 70 years per
GP in 2007 [7,9]. The proportion of GPs with reliability
>0.7 and >0.8 for each STOPP indicator and the com-
posite were then calculated based on the actual number
of patients in each GP practice [7].
Multilevel logistic regression investigated how the
STOPP composite indicator varied between GPs and by
patient and GP characteristics. Multilevel unadjusted
odds ratios (OR) with 95% confidence intervals (CI)
were estimated in a two level random intercept logistic
model for each patient level one explanatory variable
(age, gender, number of different repeat drug classes)
and each GP level two explanatory variables (gender,
urban/rural, deprivation). Three multivariable models
were estimated; (i) Model 1, a two level random inter-
cept logistic model with patient level one explanatory
variables only; (ii) Model 2, a two level random intercept
logistic model with patient level one and GP level two
explanatory variables and; (iii) Model 3, a two level ran-
dom slope logistic model. In Models 1 and 2, the re-
sponse probability for the STOPP composite indicator
was allowed to vary across GPs but the effect of each pa-
tient level one explanatory variable was assumed to be
the same for each GP. Model 3, allowed both the inter-
cept and the explanatory variable, number of different
repeat drug classes, to vary randomly across GPs [15].
Likelihood ratio (LR) tests were used to compare the fit



















Figure 1 The proportion of PIP prescribing (at least one
potentially inappropriate indicator) for each GP (N=1,938).
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coefficient (VPC) were estimated for all three models
[15]. The VPC partitions the variance at the patient and
GP level and provides an estimate of the proportion of
the total residual variance of the outcome (PIP) that is
explained at the GP level and represents the heterogen-
eity between the GPs. The VPC was initially calculated
in an “empty” model including only the random param-
eter (PIP). Patient level and GP level variables were then
introduced into the model and the percentage of propor-
tional change in variance was calculated, representing
the percentage of variation explained by the variables in
the model compared with the empty model. The median
odds ratio (MOR) was also calculated which quantifies the
variation between GPs by comparing two patients from
two randomly chosen, different GPs [16]. A MOR equal to
1 indicates no differences between GPs in the probability
of prescribing a PIP indicator. The variation between GPs
after controlling for patient level variables (Model 1) was
examined graphically using a funnel plot of the observed
versus expected number of patients with a PIP indicator
and compared to the unadjusted analysis [17].
Initial data analysis and application of the STOPP cri-
teria to the data set was performed using SAS statistical
software package version 9.1 (SAS Institute Inc. Cary,
NC, USA). Multilevel logistic regression was performed
in STATA Version 11.2 (StataCorp, Texas, USA) [18].
Level two residuals were checked graphically for normal-
ity, heteroskedasticity and outliers.
Results
Descriptive statistics
A total of 1,938 GPs and 338,725 patients aged ≥ 70 years
were identified from the HSE-PCRS pharmacy claims
database. The variation between GPs in the overall rate
of PIP was considerable ranging from 13% at the 5th per-
centile to 65% at the 95th percentile (median 35%, IQR
29.6-40.3%). Figure 1 presents the proportion of PIP
(at least one PIP indicator) for each GP. GPs outside the
3 standard deviation (SD) control limit were statistically
significantly different from the average. Common cause
variation is when the values are within the 2 SD and 3
SD lines and special cause variation is when the values
are outside the 3 SD lines. Common cause variation indi-
cates variation consistent with random chance and spe-
cial cause variation indicates variation due to systematic
influences [19]. Ninety-eight percent of GPs (N = 1,906)
had at least one patient with PIP.
Reliability of STOPP criteria
All of the thirty STOPP criteria had adequate reliability
(> 0.7) based on a GP with median-sized catchment. The
majority of practitioners had sufficient patient numbers
aged ≥ 70 years to be reliably measured for each of theindividual STOPP criteria. Between 82.6% and 99.9% of
practitioners had reliability > 0.7 and between 70.1% and
97.2% had reliability > 0.8. The reliability of the compos-
ite STOPP indicator for a median sized GP was 0.80.
The proportion of practitioners with sufficient patient
numbers to be reliably measured was lower than the in-
dividual STOPP criteria; 76.6% had reliability > 0.7 and
60% had reliability > 0.8 (Additional file 1).
Multilevel regression model
Table 1 shows the percentage of patients receiving at
least one PIP indicator by patient and GP characteristics
and the unadjusted ORs with 95% CIs estimated in a
two level random intercept logistic model. PIP increased
considerably with the number of different repeat drug
classes; 3% of patients with no repeat prescriptions re-
ceived a PIP indicator compared with 70% of those pre-
scribed ≥10 repeat drug classes. PIP also increased with
age. PIP varied less by GP level variables with a higher
rate in urban based practices compared to rural.
Table 2 presents the adjusted ORs and 95% CIs for the
three multivariate models (Models 1, 2 and 3). In the
multivariate model including only patient level variables
(Model 1) the association between PIP and the number
of different repeat drug classes was mainly unchanged
compared to the unadjusted ORs (Table 1). The associa-
tions with patient gender and age were reversed, with
older patients and female patients slightly less likely to
receive a PIP indicator. In the two level random inter-
cept logistic model with no explanatory variables (empty
model) the between GP variance was 9% (SE 0.004). In
Model 1, after adjusting for patient level variables the re-
sidual between GP variance in receiving a PIP indicator
was 6% (SE 0.003).
The multivariate model including both patient and GP
level variables (Model 2) had similar findings with the
association between PIP and number of different repeat
Table 1 Number and percentage of patients receiving at least one potentially inappropriate indicator and multilevel
unadjusted odds ratios (95% CIs)
Total number of
patients N = 338,725
N (%) prescribed
at least one PIP
Multilevel unadjusted
OR* (95% CIs)
Patient level fixed effects
Gender
Male 144,316 49,517 (34) 1
Female 194,409 71,592 (37) 1.12 (1.10, 1.13)
Age
70-74 years 128,261 41,304 (32) 1
≥ 75 years 210,464 79,805 (38) 1.30 (1.28, 1.32)
No of different repeat drug classes
0 28,259 950 (3) 1
1 19,533 1,278 (6) 2.01 (1.85, 2.19)
2 24,013 2,892 (12) 3.97 (3.68, 4.28)
3 28,970 5,149 (18) 6.29 (5.85, 6.75)
4 32,742 7,505 (23) 8.72 (8.13, 9.35)
5 33,538 10,078 (30) 12.64 (11.80, 13.54)
6 32,984 12,089 (37) 17.14 (16.00, 18.36)
7 29,738 12,984 (44) 22.94 (21.41, 24.57)
8 25,574 12,753 (50) 29.58 (27.59, 31.71)
9 20,908 11,755 (56) 38.12 (35.52, 40.91)
≥10 62,466 43,676 (70) 69.96 (65.40, 74.83)
GP practice level fixed effects† No of GPs N = 1,938 % prescribed at least one PIP Multilevel unadjusted OR (95% CI)
Gender‡
Male 1,359 1,344 (99) 1
Female 557 450 (97) 0.98 (0.94, 1.01)
Area of residence
Urban 1,438 1,408 (98) 1
Rural 500 470 (94) 0.89 (0.86, 0.92)
Deprivation Median IQR
Deprivation 0.68 1.91 1.03 (1.02, 1.04)
*OR = odds ratio.
†GP level data was unavailable for 108 (5%) GPs with 6,906 (2%) patients.
‡GP gender was missing for 22 (1%) GPs with 2,578 (0.76%) patients.
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tween PIP and GP area of residence (urban/rural) was
no longer significant compared to the unadjusted ORs
(Table 1). Adding GP level variables (Model 2) only ex-
plained an additional 0.5% of the between GP variance
(Model 2 = 5.9% vs. Model 1 = 6.4%) and resulted in
minimal change to the adjusted ORs. Model 3 allowed
the coefficient of the number of different repeat drug
classes to vary randomly across GPs. LR tests indicated
that Model 3 was preferred to Models 1 and 2. Model 3
indicated that the between GP variance for PIP was a
quadratic function of the number of different repeat
drug classes. The lower or higher the number of repeat
drug classes the more variability in PIP between GPs.Figure 2 shows the differences between the observed
numbers of patients with a PIP indicator from the ex-
pected, for each GP after adjustment for patient level ex-
planatory variables (Model 1). GPs varied from having
50% less than the expected rates of PIP to 50% to 100%
in excess but the majority of this variation was not sig-
nificant (within 3 SD). GPs outside the three standard
deviation control limits were statistically significantly
different from the average. The VPC for the “empty”
model which explains the percentage variance explained
by the GP level was 2.7% and relatively small. This indi-
cates that individual patient factors are relatively more
important for PIP than GP level factors. The VPC for
Model 2 was 1.76%. Thus after adjusting for the effects
Table 2 Multilevel logistic regression adjusted odds ratios (95% CIs) for patients receiving at least one potentially
inappropriate indicator
Variable Model 1 random intercept
patient level variables
Model 2 random intercept
patient and GP level variables
Model 3 random slope
patient and GP level variables
OR* (95% CIs) OR* (95% CIs) OR* (95% CIs)
Patient level fixed effects
Gender
Male 1 1 1
Female 0.92 (0.90, 0.93) 0.92 (0.90, 0.93) 0.92 (0.91, 0.93) 1
Age
70-74 years 1 1 10,(0.95)
≥ 75 years 0.95 (0.93, 0.97) 0.95 (0.93, 0.97) 0.95 (0.93, 0.96)
No of different repeat drug classes
0 1 1 1
1 2.00 (1.83, 2.18) 2.00 (1.83, 2.18) 1.43(1.43, 1.44) †
2 3.98 (3.69, 4.30) 3.98 (3.68, 4.30)
3 6.31 (5.87, 6.79) 6.31 (5.86, 6.78)
4 8.81 (8.20, 9.46) 8.81 (8.20, 9.45)
5 12.79 (11.92, 13.72) 12.78 (11.91, 13.71)
6 17.39 (16.21, 18.65) 17.38 (16.20, 18.64)
7 23.22 (21.65, 24.92) 23.21 (21.63, 24.90)
8 30.15 (28.09, 32.37) 30.13 (28.07, 32.35)
9 38.89 (36.19, 41.79) 38.86 (36.17, 41.76)
≥10 71.77 (67.00, 76.87) 71.71 (66.95, 76.81)
GP level fixed effects‡
Gender§
Male - 1 1
Female - 0.94 (0 .91, 0.97) 0.94 (0.91, 0.97)
Area of residence
Urban - 1 1
Rural - 0.98 (0.95, 1.01) 0.98 (0.94, 1.01)
Deprivation
Deprivation score (centred) - 1.00 (0.99, 1.01) 1.00 (0.99, 1.01)
*OR = odds ratio.
†The number of different repeat drug classes was treated as a continuous variable (created 10 dummy variables and the coefficients show an approximately
linear increase).
‡GP level data was unavailable for 108 (5%) GPs with 6,906 (2%) patients.
§GP gender was missing for 22 (1%) GPs with 2,578 (0.76%) patients.
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(1.76%) in the propensity for PIP at the GP level was at-
tributable to unobserved patient and GP characteristics.
The GP level variance was also measured by the MOR
(MOR 1.26; 95% CI: 1.23 to 1.29) [16].
Discussion
Principal findings
There was a high prevalence of PIP in those aged
≥70 years in Ireland in 2007 and nearly all GPs had at
least one patient with PIP. The most prevalent PIP drugs
were PPIs at maximum therapeutic dosage for >8 weeks,followed by NSAIDs for >3 months and long-acting ben-
zodiazepines for >1 month. The National Institute for
Health and Clinical Excellence (NICE) guidelines recom-
mend regular review of patients to assess their continu-
ing need for PPIs and the use of step-down therapy
[20]. Long-term PPI treatment has significant cost
consequences [21,22]. NSAID use is associated with
gastrointestinal adverse effects and hospitalisation and
long-acting benzodiazepines are associated with an in-
creased risk of falls, fractures, impaired cognition and
dependence problems in older populations [23,24]. Drug
duplication on the same prescription claim was also
Figure 2 Observed versus expected number of patients with a
potentially inappropriate indicator (N=1,938).
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to increase the risk of gastrointestinal toxicity [25].
The individual STOPP indicators can be used with
reasonable confidence to identify GPs as having above
or below average proportions of PIP (average > 0.8 reli-
ability for 90% of GPs). Although the composite indicator
had lower reliability, it is likely in practice that the individ-
ual indicators would be used to monitor the quality of pre-
scribing. There is also evidence that the STOPP criteria
have predictive validity with an association found between
STOPP and ADEs in older hospitalised patients [26].
There was relatively little variation in PIP between
GPs in Ireland at the GP level, the majority of the vari-
ation was at the patient level. While there was evidence
of significant variation in PIP between GPs in the un-
adjusted analysis (Figure 1) after adjustment for patient
level variables the majority of this remaining variation
was no longer significant (Figure 2). This remaining vari-
ation (significant and non-significant) was not explained
by adding GP level variables to the model. The charac-
teristics of the GPs did not substantively affect the likeli-
hood of receiving a PIP indicator at the patient level.
The multilevel logistic regression model for the STOPP
composite indicator found that only the number of dif-
ferent repeat drug classes was strongly associated with
the likelihood of receiving a potentially inappropriate in-
dicator. Other patient and GP level variables were found
to be significantly associated with PIP but their odds ra-
tios were close to one in the adjusted multilevel models.
The association between the number of different repeat
drug classes and the likelihood of receiving a potentially
inappropriate indicator varied across GPs; the lower or
higher the number of repeat drug classes the more vari-
ability in PIP between GPs.
A recent Scottish study investigated the variation in
PIP between 315 practices and 139,404 patients defined
as vulnerable to ADEs using 15 indicators based onexplicit national prescribing safety advice (median 12.5%,
IQR, 10.1%, 15.3%) [7]. Unlike the current study, the
variation between practices was considerable even after
adjusting for patient case mix and practice characteris-
tics. Practices which were statistically different from
average varied from having half (−50%) the expected
rates of PIP prescribing to having 50%-125% in excess.
The MOR was higher than the current study (1.42, 95%
CI, 1.37, 1.47) [7]. The study populations and prevalence
of PIP were different for the two studies which may ex-
plain the differences in variation between prescribers [7].
Both studies did however identify considerable unex-
plained significant and non-significant variation in PIP
between prescribers and found that practice level vari-
ables did not account for this variation (additional 0.5%
in both studies); only the patient level factor number of
drug classes was strongly associated with PIP [7].
This study has identified that reductions in PIP will re-
quire improvement across all GPs to reduce the average
rate of PIP rather than focusing on a few select GPs
(outliers). The number of different repeat medications has
consistently been shown to be an independent predictor
for PIP in numerous studies [7,14,27-29]. The prescription
of multiple medications in older adults has also been asso-
ciated with an increased risk of drug interactions, adher-
ence problems, ADEs and drug costs [27,30]. There is
some evidence that interventions targeting polypharmacy
in older people, using pharmaceutical care or compu-
terised decision support, are successful in reducing medi-
cation related problems such as PIP. These and other
forms of interventions that help the prescriber modify or
reduce PIP in older patients should be developed and eval-
uated in randomised controlled trials [30].
Strengths and limitations
This study has a number of limitations. The lack of diag-
nostic information in the database limited the applicabil-
ity of all of the STOPP criteria and the investigation of
individual patient factors and differences in drug indica-
tion. It is likely that estimates of PIP and comparisons
across GPs are conservative. [31] There was a possibility
of confounding by indication and patient case mix when
comparing PIP rates across different GPs. However, the
variable number of different repeat drug classes should
account for most of the unmeasured variability in pa-
tient co-morbidities between GPs.
There was a small proportion of patients (3.5%) who
were assigned to more than one GP in 2007 and these
patients were assigned to the GP who prescribed their
medication on a consistent basis, or their most recent
GP if more than one GP prescribed their medication on
a consistent basis. Therefore, a certain proportion of
prescribing is unaccounted for in the analysis which
may result in a more conservative estimate of PIP. In
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though this is not likely to be a significant factor as the
scheme provides free medical treatment and patients
must pay for OTC items.
The multilevel approach used in this study controlled
for confounding by including both patient and GP level
predictors of PIP. In general GP variation in prescribing
reflects different therapeutic approaches to health prob-
lems in older populations but the current study found
minimum variation in PIP between GPs. Also none of
the available patient and GP level factors could explain
the remaining variation in PIP between GPs. The data-
base had a limited number of GP and patient variables,
hence limiting the ability to explain all of the remaining
variance. Further multilevel research is required to investi-
gate and understand which factors influence PIP at the
different levels of health care organisation; patient, GP,
and practice organisation and culture [7,32].
Notwithstanding the limitations, this study is one of
the first studies to examine how PIP varies between both
patients and GPs in a national older population [7]. The
application of PIP indicators to prescription databases at
the patient, GP and practice level provides useful infor-
mation for assessing and comparing prescribing at the
population level [33].
Policy implications
The development of PIP guidelines and their implemen-
tation is expensive and must bring value in terms of im-
proved prescribing quality and patient outcomes. Studies
on the effectiveness of clinical guidelines have been
conflicting but they are effective if well constructed and
implemented consistently. Guidelines also need to be
closely monitored and prescribers educated to comply
with them [34-36]. The introduction of regulatory pre-
scribing guidelines were poorly followed in France be-
cause of the volume, lack of information systems and
limited capacity for monitoring [37]. While in the UK,
education on the use of guidelines on prescribing nutri-
tional supplements significantly reduced total prescrib-
ing by 15% and inappropriate prescribing from 77% to
59% [38]. The use of computerised clinical decision sup-
port, academic detailing and pharmacist intervention has
had some success in reducing PIP and further research
on their implementation is required [39-42].
There is also evidence that guidelines are effective if
accompanied by pay for performance financial incentives
[43]. Performance measurements do offer an efficient
mechanism to regulate health care providers, increase
accountability and encourage quality improvement and
care but can alienate providers and make them obstinate
to change [44-46]. Not all PIP measured in prescribing
databases may be inappropriate and screening tools will
never be substitutes for clinical assessment and judgment.However they can be used to identify high rates of PIP
and monitor and improve prescribing practices in older
populations.
Conclusion
Optimisation of drug prescribing in older patients is be-
coming an important public health issue worldwide and
effective mechanisms and policies are needed to reduce
the occurrence of PIP across all GPs and improve the
quality of prescribing [31].
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